Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NovaMed Raises $14 Million to In-license New Molecules

publication date: Jan 22, 2008

NovaMed Pharmaceuticals Inc., a CRO and out-sourced distribution company based in Shanghai, announced that it has closed a Series B funding round worth $13.8 million. In May 2007, the company raised $5 million in an A round. NovaMed was founded in 2005. NovaMed said that it would use the money to in-license new molecules to develop in China, expand its sales/distribution organization and build up its R&D capacity. More details...

Stock Symbols: (NYSE: WX) (NYSE: SNY) (NYSE: BAX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here